Emeis (WBO:ORP2) Other Long-Term Liabilities: €819 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:ORP2 Emeis WBO:ORP2
56 GF Score
Price €14.28
GF Value €11.68
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Emeis Other Long-Term Liabilities?

Emeis WBO:ORP2 -1.04% 56 Other Long-Term Liabilities is €819 Mil as of Jun. 2026. GuruFocus rates WBO:ORP2 with a GF Score™ of 56/100 and a GF Value™ of €11.68 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Emeis's other long-term liabilities for the quarter that ended in Jun. 2026 was €819 Mil.

Emeis's quarterly other long-term liabilities declined from Jun. 2025 (€865 Mil) to Dec. 2025 (€613 Mil) but then increased from Dec. 2025 (€613 Mil) to Jun. 2026 (€819 Mil).

Emeis's annual other long-term liabilities declined from Dec. 2023 (€970 Mil) to Dec. 2024 (€924 Mil) and declined from Dec. 2024 (€924 Mil) to Dec. 2025 (€613 Mil).

Emeis Other Long-Term Liabilities Related Terms

Emeis Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Emeis's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emeis Other Long-Term Liabilities Chart

Emeis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,145.45 1,110.19 969.55 924.36 612.92

Emeis Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 967.02 924.36 865.07 612.92 818.67
WBO:ORP2
56GF Score
Emeis WBO:ORP2
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emeis Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €819 Mil mean?
Emeis (WBO:ORP2) has a Other Long-Term Liabilities of €819 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Emeis and its competitors.
Is Emeis' Other Long-Term Liabilities too high?
Emeis' current Other Long-Term Liabilities is €819 Mil. Overall, Emeis has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emeis' Other Long-Term Liabilities compare to HCA and THC?
Emeis' Other Long-Term Liabilities of €819 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Healthcare Providers & Services company?
A good Other Long-Term Liabilities depends on the Healthcare Providers & Services industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Emeis and its competitors. Emeis's current Other Long-Term Liabilities is €819 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emeis stock overvalued right now?
Based on GuruFocus' analysis, Emeis (WBO:ORP2) is currently considered Modestly Overvalued. The stock's GF Value™ is €11.68, compared to a current price of €14.28 — trading 22.3% above its estimated fair value. The current Other Long-Term Liabilities is €819 Mil. Emeis' overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Emeis (WBO:ORP2), the current Other Long-Term Liabilities is €819 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emeis (WBO:ORP2) Overvalued in 2026?

Based on GuruFocus' analysis, Emeis stock appears to be overvalued. The current stock price of €14.28 is trading 22.3% above its estimated GF Value™ of €11.68. GuruFocus considers Emeis to be Modestly Overvalued.

Key valuation signals for WBO:ORP2:

  • Other Long-Term Liabilities: €819 Mil
  • GF Value™: €11.68 vs. price of €14.28 (22.3% above fair value)
  • GF Score™: 56/100 with 8 warning signs

No single metric tells the full story. See the WBO:ORP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emeis Business Description

Address 12, Rue Jean Jaures, CS 10032, Puteaux Cedex, Paris, FRA, 92 813
Emeis operates a comprehensive care offering of mental health clinics and medical and rehabilitation care, retirement homes, assisted living and home care.
56GF Score

Get the complete analysis for WBO:ORP2

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.28
Price
€11.68
GF Value